medline.ch Onkologie Urologische Tumoren

	Assessing Levels of Evidence for Cancer Screening: A Focus on Testicular Self-examination. Cancer Prev Res (Phila) Thomas K, Malvita A, Rovito MJ. PMID: 42817620 [PubMed - indexed for MEDLINE]
	Rezvilutamide in metastatic hormone-sensitive prostate cancer: interpreting CHART trial evidence and clinical applicability in the European Association of Urology guidelines. BJU Int Mi L, Li S, Huo B. PMID: 42817232 [PubMed - as supplied by publisher]
	Novel Approaches in Bladder Cancer Diagnosis and Treatment. Curr Med Chem Shaikh AN, Ginayatova I, Malikova I, Kriajevska M. PMID: 42817083 [PubMed - as supplied by publisher]
	Generalizability of a biopsy-trained artificial intelligence algorithm to TURP and HoLEP specimens for detection of incidental prostate adenocarcinoma. Diagn Pathol Yeldir N, Uzel B, Tekin EN, Y, Tekin E, Çay, Co, Müezzino. PMID: 42816888 [PubMed - indexed for MEDLINE]
	Re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion-targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.06.020. Eur Urol Lombardo R, Santioni M, De Nunzio C. PMID: 42816310 [PubMed - as supplied by publisher]
	Stereotactic Body Radiation Therapy in Oligometastatic Castration-resistant Prostate Cancer: Time to Move from Signals to Phase 3 Trial Evidence. Eur Urol Pasquier D, Flippot R, Fizazi K, PEACE-8 investigators. PMID: 42816309 [PubMed - as supplied by publisher]
	Re: [(177)Lu]Lu-PSMA-617 in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-naive/sensitive Prostate Cancer (PSMAddition): A Phase 3 Randomised, Controlled Trial. Eur Urol Viti A, Cucchiara V, Gandaglia G, Briganti A, Montorsi F. PMID: 42816307 [PubMed - as supplied by publisher]
	Intermittent fasting versus continuous calorie energy reduction in prostate cancer patients on active surveillance. Transl Behav Med Yeary KHK, Yu H, Hussein AA, Varady K, DiCarlo E, Escaldi A, Tang L. PMID: 42816069 [PubMed - indexed for MEDLINE]
	Prostate cancer screening: Evidence uncertainty and implications for patient education and counseling. Patient Educ Couns Takahashi T. PMID: 42815281 [PubMed - as supplied by publisher]
	Ethnic and Geographic Variation in Prostate Cancer Presentation in Suriname. JCO Glob Oncol Wielzen HA, Sandel NJ, Ramsoekh A, Baktawar S, Chan M, Vis AN, Pigot GLS. PMID: 42814916 [PubMed - indexed for MEDLINE]
	Patients' and Physicians' Perceptions of AI Integration in Prostate Cancer Diagnosis: Mixed Methods Study of Challenges to the Patient-Physician Relationship. J Med Internet Res Koshmanova E, Kirkove D, Voz B, Gillain N, Matagne A, Bruwier L, Waltregny D, Pétré B. PMID: 42814749 [PubMed - indexed for MEDLINE]
	Immunometabolic effects of oral testosterone for castration-resistant prostate cancer in the ACROBAT trial. Mol Cancer Res Zipkowitz S, Redinger K, Jonnatan S, Vakkala V, Lu J, Schultz K, Rifkind I, Michalik A, King S, McIntyre K, Sinibaldi V, Markowski MC, Marshall CH, Paller CJ, Wang H, Mao SS, Denmeade SR, Sanin DE, Thompson EA, Sena LA. PMID: 42814510 [PubMed - as supplied by publisher]
	Defining the Role of Single-Port Robotic Partial Nephrectomy: Current Evidence, Patient Selection, and Anatomy-Platform Matching. Curr Urol Rep Hevia V, Sánchez-Carpena J, Cámara-Martínez C, Lista-Mateos F. PMID: 42814206 [PubMed - indexed for MEDLINE]
	Adult intratesticular splenogonadal fusion simulating testicular cancer: a diagnostic blind spot in modern urologic oncology. J Surg Case Rep El Nabbout G, Kowalczyk JJ, Manahan KJ. PMID: 42813151 [PubMed]
	Missed Diagnosis of Clear Cell Renal Cell Carcinoma on Noncontrast Computed Tomography: The Potential Role of Artificial Intelligence in Reducing Radiological Diagnostic Error. Case Rep Nephrol Abenavoli FM, Tujjar O, Alfonso A. PMID: 42813057 [PubMed]
	Salvage Metastasis-Directed Therapy Without Androgen Deprivation for Positron Emission Tomography-Defined Oligorecurrent Prostate Cancer: Results of the SOAR Phase II Trial. JU Open Plus Crockett E, Schmidt B, Rodriguez O, Taylor A, Braun E, Leonhart S, Swami U, Boucher KM, Chapman L, Davis H, Linton J, Mangelson E, Johnson S, Tward J, Odei B, Yap J, Gupta S, Kohli M, Agarwal N, Dechet C, O'Neil B, Maughan BL, Sanchez A. PMID: 42812884 [PubMed]
	Unravelling therapeutic resistance: role of cancer stem cell and microRNA in metastatic prostate cancer. Front Mol Biosci Moondra H, Choudhary GR, Ahirwar DK, Banerjee M, Shukla SK, Shukla KK. PMID: 42812781 [PubMed]
	PROK1 Expression Is Associated With Prognosis and May Influence Response to Antiandrogen Therapy in Prostate Cancer. Prostate Cancer Lu DJ, Liang HQ, Li YJ, Yu JY, Wei LW, Mo QZ, Zhao JW, Nong RJ, Wang YY, Zhang XP, Qin M, Cheng JW. PMID: 42812728 [PubMed]
	BRCA-Mutated Prostatic Adenocarcinoma: A Distinct Clinicopathological Subset With Frequent Cribriform Morphology Associated With Domain-Specific Alterations in Putative Protein Properties. Front Biosci (Schol Ed) Kurt S, Krishnamurthy K. PMID: 42812039 [PubMed - indexed for MEDLINE]
	Label-free optical biomarker for prostate cancer diagnosis. Mol Med Alam SR, Siller K, Dreicer R, Periasamy A. PMID: 42811292 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 181844

Seite 1 von 9093

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung